All In Biotech

NDA 022307 · Cosette

Effient

Prasugrel Hydrochloride · Oral

NovelPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Dec 22, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2009

Jul 10, 2009

Approved uses

3

Original approval plus efficacy supplements

Registered trials

209

48 Phase 3, 21 recruiting

FAERS reports

10,151

7,609 serious, 862 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: BLEEDING RISK Effient can cause significant, sometimes fatal, bleeding [see Warnings and Precautions (5.1 , 5.2) and Adverse Reactions (6.1) ] . Do not use Effient in patients with active pathological bleeding or a history of transient ischemic attack (TIA) or stroke [see Contraindications (4.1 , 4.2) ] . In patients ≥75 years of age, Effient is generally not recommended, because of the increased risk of fatal and intracranial bleeding and uncertain benefit, except in high-risk situations (patients with diabetes or a history of prior myocardial infarction [MI]) where its effect appears to be greater and its use may be considered [see Use in Specific Populations (8.5) ] . Do not start Effient in patients likely to undergo urgent coronary artery bypass graft surgery (CABG). When possible, discontinue Effient at least 7 days prior to any surgery [see Warnings and Precautions (5.2)...

What it is approved for

From the label in effect Sep 7, 2022.

Effient is a P2Y 12 platelet inhibitor indicated for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are to be managed with percutaneous coronary intervention (PCI) as follows: Patients with unstable angina or non-ST-elevation myocardial infarction (NSTEMI) ( 1.1 ). Patients with ST-elevation myocardial infarction (STEMI) when managed with either primary or delayed PCI ( 1.1 ). 1.1 Acute Coronary Syndrome Effient ® is indicated to reduce the rate of thrombotic CV events (including stent thrombosis) in patients with acute coronary syndrome (ACS) who are to be managed with percutaneous coronary intervention (PCI) as follows: Patients with unstable angina (UA) or non-ST-elevation myocardial infarction (NSTEMI). Patients with ST-elevation myocardial infarction (STEMI) when managed with primary or delayed PCI. Effient has been shown to reduce the rate of a combined endpoint of cardiovascular death, nonfatal myocardial infarction (MI), or nonfatal stroke compared to clopidogrel. The difference between treatments was driven predominantly by MI, with no difference on strokes and little difference on CV death [see Clinical Studies (14) ] .

Mechanism: Prasugrel is an inhibitor of platelet activation and aggregation through the irreversible binding of its active metabolite to the P2Y 12 class of ADP receptors on platelets.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • EFFIENT · PRASUGREL HYDROCHLORIDE EQ 10MG BASE · TABLET, ORAL · Prescription · TE AB
  • EFFIENT · PRASUGREL HYDROCHLORIDE EQ 5MG BASE · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Prasugrel" as an intervention, any sponsor and status, largest first.

All 209 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • myocardial infarction510
  • gastrointestinal haemorrhage472
  • chest pain460
  • haemorrhage454
  • dyspnoea436
  • contusion425
  • fatigue333
  • off label use324
  • nausea308
  • dizziness302
  • thrombosis in device284
  • epistaxis254

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20081
200956
2010598
2011786
2012827
2013502
2014545
20152,703
2016817
2017667
2018503
2019414
2020259
2021216
2022379
2023321
2024167
2025209
2026181

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Effient (Prasugrel HCl)

2024 spending

$903K

Beneficiaries

188

858 claims

Per beneficiary

$4,805

$18.03 per unit

View as table
YearSpending
2020$0
2021$0
2022$154,137
2023$1,033,195
2024$903,432

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 652 on PubMed

Sponsor: Cosette

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.